Priority Review Vouchers Appear To Be Dropping In Price
Executive Summary
Gilead spent less than $338m for the coupon entitling it to a speedier FDA review, down at least $12m from AbbVie's high-water purchase price almost a year ago.
You may also be interested in...
Drug Pricing: Could Expedited Review Of Competing Brands Create The Desired Pressure?
Payer groups suggest during FDA's Hatch-Waxman meeting that agency prioritize NDAs moving into the same class to push prices lower.
Drug Pricing: Could Expedited Review Of Competing Brands Create The Desired Pressure?
Payer groups suggest during FDA's Hatch-Waxman meeting that agency prioritize NDAs moving into the same class to push prices lower.
Gilead Buys Its Third Priority Review Voucher, But Is The Mania Over?
Just as the tulip craze eventually subsided, it appears the pharma industry's infatuation with priority review vouchers also may be waning, as Sarepta sells its voucher for only $125m.